On the other hand, studies exist which claim that no beneficiary effect was seen by the use of IFN in treating MM patients [83]; further, to reap the benefits from the IFN-γ immunomodulating feature, a schedule of IFN-γ therapy should be implemented [84]. Here, IFNG is linked to Miyoshi myopathy.